睿知中国疾病研究地图
候选清单0

正在招募肝细胞癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma

ClinicalTrials.gov 上登记的一项肝细胞癌开放试验,由北京协和医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方北京协和医院Peking Union Medical College Hospital北京医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07014150,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Hepatocellular carcinoma diagnosed by histology or imaging

    入选标准第 3 条

  3. Hypertension that has not been well controlled after antihypertensive drug treatment (systolic blood pressure >160mmHg, diastolic blood pressure >100mmHg)

    排除标准第 12 条

    Positive for active hepatitis B or hepatitis C and has not received regular treatment. During the screening period, HBV DNA≥2000 IU/ml (or ≥104 copy number /ml), entecavir must be used to reduce it to <2000 IU/ml (or < 104 copy number /ml) before enrollment

    排除标准第 19 条

    Unresolved toxicity of grade > 1 due to any previous treatment/procedure (CTCAE 5.0, excluding alopecia, anemia, and hypothyroidism).

    排除标准第 21 条

    Received treatment with potent CYP3A4 inhibitors within 7 days before participating in the study

    排除标准第 23 条

    Accompanied by other malignant tumors, but having had other untreated malignant tumors in the past (within 5 years) or simultaneously, for cured basal cell carcinoma of the skin, squamous cell carcinoma of the skin, carcinoma in situ of the breast and carcinoma in situ of the cervix, treated superficial bladder cancer and prostate adenocarcinoma that has undergone surgical treatment and whose PSA tumor markers are within the normal range.

    排除标准第 24 条

  4. The ECOG score was 0-1 within one week before enrollment

    入选标准第 8 条

    ECOG score >1

    排除标准第 2 条

  5. Insufficiency of liver and kidney functions, such as jaundice, ascites, and/or bilirubin >3×ULN, creatinine ratio >3.5g/24 hours, etc

    排除标准第 9 条

  6. At least one measurable lesion (according to the requirements of RECIST version 1.1, the long diameter of the measurable lesion on spiral CT scan is ≥10mm or the short diameter of the enlarged lymph node is ≥15mm)

    入选标准第 4 条

  7. History of human immunodeficiency virus (HIV) infection

    排除标准第 18 条

  8. Fertile women: Agree to abstain from sex (avoid heterosexual intercourse) or use contraceptive methods with an annual contraceptive failure rate of less than 1% during the treatment period and for at least 6 months after the last administration

    入选标准第 10 条

    Pregnant women (with a positive pregnancy test before taking the medicine) or lactating women

    排除标准第 4 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义)。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07014150,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. The subjects voluntarily participated in the study and agreed to sign the written informed consent. They had good compliance and cooperated with the follow-up
  2. Be at least 18 years old at the time of signing the informed consent form, with no gender restrictions.
  3. Hepatocellular carcinoma diagnosed by histology or imaging
  4. At least one measurable lesion (according to the requirements of RECIST version 1.1, the long diameter of the measurable lesion on spiral CT scan is ≥10mm or the short diameter of the enlarged lymph node is ≥15mm)
  5. No systematic treatment has been received before
  6. CNLC:Ib to IIIa
  7. There is at least one of the following high-risk factors for postoperative recurrence: AFP>400ng/ml; Single tumor >5cm; The number of tumors is greater than 3 or any one of them is greater than 3cm; There are vascular tumor thrombus or tumors adjacent to large blood vessels, etc.
  8. The ECOG score was 0-1 within one week before enrollment
  9. Hematology and organ functions are adequate
  10. Fertile women: Agree to abstain from sex (avoid heterosexual intercourse) or use contraceptive methods with an annual contraceptive failure rate of less than 1% during the treatment period and for at least 6 months after the last administration

排除标准:Exclusion Criteria:

  1. Have received any systemic treatment
  2. ECOG score >1
  3. Definite extrahepatic metastasis
  4. Pregnant women (with a positive pregnancy test before taking the medicine) or lactating women
  5. Those who are known to be allergic or intolerant to recombinant humanized PD-1 monoclonal antibody drugs and their components (or any excipients)
  6. Previous or existing grade 3 or above digestive tract fistulas or non-digestive tract fistulas (such as skin) as defined by CTCAE 5.0 criteria
  7. Major surgical operations (except biopsy) have been performed within 4 weeks before the first study of drug treatment or the surgical incision has not fully healed
  8. Cardiovascular and cerebrovascular diseases with significant clinical significance, including but not limited to acute myocardial infarction and severe/unstable angina pectoris that occurred within 6 months before enrollment
  9. Insufficiency of liver and kidney functions, such as jaundice, ascites, and/or bilirubin >3×ULN, creatinine ratio >3.5g/24 hours, etc
  10. Persistent infection of grade >2 (CTCAE 5.0)
  11. A history of thromboembolism (including stroke and/or transient ischemic attack) within the past 6 months
  12. Hypertension that has not been well controlled after antihypertensive drug treatment (systolic blood pressure >160mmHg, diastolic blood pressure >100mmHg)
  13. An active autoimmune disease or a history of autoimmune diseases in the past two years
  14. Active central nervous system (CNS) metastases and/or cancerous meningitis
  15. Be ready or have received organ or allogeneic bone marrow transplants before
  16. Known history of active tuberculosis (Mycobacterium tuberculosis)
  17. A history of gastrointestinal bleeding within the past 6 months or a clear tendency towards gastrointestinal bleeding
  18. History of human immunodeficiency virus (HIV) infection
  19. Positive for active hepatitis B or hepatitis C and has not received regular treatment. During the screening period, HBV DNA≥2000 IU/ml (or ≥104 copy number /ml), entecavir must be used to reduce it to <2000 IU/ml (or < 104 copy number /ml) before enrollment
  20. There is drug abuse; Or any medical, psychological or social conditions that may affect the research, cause unstable patient compliance, or even endanger patient safety
  21. Unresolved toxicity of grade > 1 due to any previous treatment/procedure (CTCAE 5.0, excluding alopecia, anemia, and hypothyroidism).
  22. Patients with objective evidence of severe lung function impairment in the past or at present, such as a history of severe pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, and drug-related pneumonia
  23. Received treatment with potent CYP3A4 inhibitors within 7 days before participating in the study
  24. Accompanied by other malignant tumors, but having had other untreated malignant tumors in the past (within 5 years) or simultaneously, for cured basal cell carcinoma of the skin, squamous cell carcinoma of the skin, carcinoma in situ of the breast and carcinoma in situ of the cervix, treated superficial bladder cancer and prostate adenocarcinoma that has undergone surgical treatment and whose PSA tumor markers are within the normal range.
  25. After a comprehensive assessment of the patient's condition by the researchers, it was determined that they were not suitable to participate in this research
  26. Participate in another clinical study

引自 ClinicalTrials.gov, NCT07014150, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07014150,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07014150